Boston Scientific has invested in Iowa Approach, a new startup devoted to its novel atrial fibrillation (AF) ablation technology. The technique is expected to be easier and cheaper than the current AF ablation procedures; there are about 400,000 ablations to treat AF annually. The company expects to be ready for testing in humans in 2016.
Bayer hopes to sell its ailing diabetes device unit to help bolster growth and fund a potential acquisition of Zoetis. The conglomerate would like to focus more closely on medicines, which has been a faster growth area than devices.
Less than a week after Boston Scientific lost its second courtroom battle over vaginal mesh implants, a federal jury ordered the company to pay $18.5 million in damages to four women who claimed the devices caused them constant pain and injuries.
Boston Scientific's Synergy bioabsorbable polymer drug-eluting stent is on track for FDA approval after the successful Evolve II clinical trial, experts said, citing data released yesterday at the American Heart Association meeting in Chicago.
Boston Scientific and Johnson & Johnson are gearing up for a courtroom showdown, as the companies prepare for a multibillion-dollar trial over a breach-of-contract suit related to a failed bidding war for devicemaker Guidant.
Boston Scientific faced a stinging setback in its ongoing vaginal mesh litigation as a federal court jury ordered the company to pay $26.7 million to four women who claimed the devices caused them undue pain and suffering.
A former Boston Scientific engineer has been indicted by a federal grand jury for stealing documents from the giant device maker that he allegedly planned to use to set up a manufacturing business in Vietnam and market the products in the U.S. and elsewhere under a new name.
Boston Scientific is shoring up for the first federal trials over its transvaginal mesh devices, countering claims from women who say the products were faulty and caused them injury.
Boston Scientific expects an FDA approval of its controversial stroke-fighting device Watchman during the first half of next year coming off its third positive FDA panel, despite a checkered regulatory past that includes a 2010 rejection due to safety concerns.
Boston Scientific won CE-mark approval for a new suite of MRI-friendly pacemaker products, boosting its product offerings and furthering its plan of revitalizing sales for its sluggish cardiac unit.